The pathophysiology of dengue virus infection remains poorly understood, although secondary infection is strongly associated with more severe disease. In the present study, we performed a nested, case-control study comparing the responses of pre-illness peripheral blood mononuclear cells between children who would subsequently develop either subclinical or symptomatic secondary infection 6-11 months after the baseline blood samples were obtained and frozen. We analyzed intracellular cytokine production by CD4
The pathophysiology of dengue virus infection remains poorly understood, although secondary infection is strongly associated with more severe disease. In the present study, we performed a nested, case-control study comparing the responses of pre-illness peripheral blood mononuclear cells between children who would subsequently develop either subclinical or symptomatic secondary infection 6-11 months after the baseline blood samples were obtained and frozen. We analyzed intracellular cytokine production by CD4
1 and CD8
1 cells in response to stimulation with dengue antigen. We found higher frequencies of dengue virus-specific TNFa, IFNc-, and IL-2-producing T cells among schoolchildren who subsequently developed subclinical infection, compared with those who developed symptomatic secondary dengue virus infection. Although other studies have correlated immune responses during secondary infection with severity of disease, to our knowledge this is the first study to demonstrate a pre-infection dengue-specific immune response that correlates specifically with a subclinical secondary infection.
Dengue is an important global health problem, and the dengue viruses (DENV) are the most prevalent arthropodborne viruses in the tropics and subtropics today. There are an estimated 50-100 million DENV infections annually worldwide [1] . The spectrum of disease ranges from subclinical infection to classical dengue fever to the more severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DHF and DSS, characterized by significant plasma leakage and occasionally hemorrhage and shock, account for an estimated half million cases and .20,000 deaths annually [2] . There are 4 distinct serotypes of dengue virus (DENV 1-4); infection with 1 serotype is believed to confer lifelong immunity to that serotype, whereas protective immunity to heterologous serotypes is short-lived, probably on the order of months [3] . One of the unique features of dengue is the role of heterologous infection in disease severity. Both clinical and epidemiological studies have suggested that the immune response plays a major role in the pathogenesis of severe dengue disease. Subsequent infection with a heterologous serotype predisposes patients toward more severe disease; studies in Southeast Asia, done both in the 1980s [4, 5] and more recently [6, 7] , have shown that DHF is associated with secondary infection, implying that other mechanisms in addition to viral replication could be the cause of DHF.
Pre-existing heterotypic immunity is believed to increase disease severity in secondary DENV infection and, thus, the risk for DHF through 2 broad hypothetical (and not necessarily mutually exclusive) pathways.
The Antibody Dependent Enhancement hypothesis proposes that pre-existing heterotypic anti-DENV IgG antibodies acquired during a previous infection can, under certain conditions, facilitate uptake of virus into macrophages and other immune cells through the binding of virus-antibody complexes to Fcc receptors. The consequent increase in receptor-mediated endocytosis leads to higher viral loads, which in turn, triggers a host inflammatory cascade that leads to DHF [8] . The second hypothesis involves cross-reactive memory T cells, which are activated during heterologous secondary infection. This leads to altered effector responses, including the generation of cytokines that may create an immunologic imbalance in response to infection and, thus, play either a protective or harmful role in the development of sequelae of infection [9] .
Our model of T cell-mediated immunopathogenesis of DENV infection postulates that the relative production of vasoactive cytokines by activated dengue-specific memory T lymphocytes influences the severity of dengue illness [10] . To our knowledge, no previous studies have looked at hostimmune factors that specifically correlate with subclinical dengue infection. We hypothesized that the memory T cell response generated during primary DENV infection is a major determinant of cytokine production during secondary infection and, therefore, influences the severity of symptoms experienced during secondary infection. Specifically, we predicted that the frequencies of dengue-specific, cytokine-producing T cells in peripheral blood mononuclear cells (PBMCs) obtained before secondary infection would correlate with the severity of disease seen in secondary infection.
To address this hypothesis, we tested PBMCs from Thai schoolchildren enrolled in a prospective cohort study [11] . The unique aspects of this study included the prospective scheduled collection and cryopreservation of PBMCs and the active surveillance for all febrile illnesses. This cohort provided an opportunity to study the predictive value of pre-infection cellular immune profiles with disease phenotype after subsequent DENV infection. From PBMCs obtained before secondary infection, we measured dengue-specific CD4 1 and CD8 1 T cell cytokine responses to dengue antigens to assess whether these responses predicted future disease severity. Because of the short interval between the collection of the baseline and follow-up blood samples, we believe that the frequencies of the DENV-specific cells at baseline reflect, as accurately as is possible in a large-scale prospective cohort, the host immune status with respect to DENV at the time of secondary infection.
MATERIALS AND METHODS

Study Design
We performed a nested, case-control study of 33 schoolchildren who were known to have developed secondary infection as part of a prospective study of primary school students in Kamphaeng Phet Province, Thailand. Using PBMCs obtained at the beginning of the enrollment period when all participants were healthy, we compared the frequency of intracellular cytokineproducing cells after stimulation with dengue antigens between 2 groups of children: one that had symptomatic dengue infection and a control group that had subclinical infection. The design of the prospective study has been reported elsewhere [11] . In brief, blood samples were collected from all participants in January 1998; plasma samples and PBMCs were cryopreserved and stored in liquid nitrogen. In addition, blood samples were collected from all participants in June, August, and November and were tested by hemagglutination inhibition (HI) to identify subclinical DENV infection, as measured by a >4-fold increase in HI titer from June through August or August through November. Study participants were monitored for school absences because of fever during the period associated with peak dengue transmission (June-November). Those participants with fever or history of fever in the prior 7 days were further evaluated with collection of acute and convalescent (.15 day) blood samples. DENV infection was identified by virus isolation and/or reversetranscriptase polymerase chain reaction (RT-PCR) of acute serum samples. The infecting DV serotype was identified from acute-phase serum samples by use of a serotype-specific RT-PCR with use of previously published methods [12] . Virus isolation in Toxorhnychites splendens mosquitoes was performed with plasma samples from all symptomatic patients with use of methods described elsewhere [13] . Serologic examination to determine primary or secondary infection used dengue IgG/IgM enzyme-linked immunosorbent assay (ELISA) and HI assays against all 4 dengue serotypes [14] . All donors during symptomatic illness had their blood samples tested by both PCR and virus isolation.
A case was considered to be symptomatic if they had a school absence with a fever or history of fever and serologic findings consistent with acute dengue infection. Subclinical DENV infection was defined as a 4-fold increase in HI antibody against any DENV serotype between 2 sequential serum samples obtained during the surveillance months (June, August, or November) without a febrile illness identified during active surveillance during the period that seroconversion occurred. Serum samples were tested concurrently for Japanese encephalitis virus (JEV)-specific HI antibody to exclude JEV infection and antibody cross-reactivity as a cause for an increase in dengue antibody.
All laboratory-confirmed virus infections were characterized according to World Health Organization guidelines for dengue fever and DHF [15] . Informed consent was obtained from all patients or their parents, and these studies were approved by the institutional review boards at the University of From the larger cohort, we identified a group of patients who, by serologic testing, were known to have developed secondary DENV infections in 1998. From this group, 33 samples were randomly selected for analysis. The persons selected represented 6 of the 12 Kamphaeng Phet schools that participated in the study. Of the samples tested, 4 were eliminated from the analysis because of inadequate cell events (,50,000 events/tube). Two patients were excluded because the pre-illness serologic findings showed no detectable (titer, ,1:10) neutralizing antibodies to any of the 4 DENV serotypes; one of these patients had a neutralizing antibody titer of 1:35 to JEV, and the other had no detectable neutralizing antibody to JEV. We compared 10 samples from children who developed symptomatic infection with 17 samples from children who had subclinical infection.
Antigen Preparation and Controls
Inactivated DENV-infected Vero cell lysates were prepared as described elsewhere [16] . Control antigens were prepared in a similar manner with use of uninfected Vero cells. The following viruses were used: DENV-1 Hawaii, DENV-2 New Guinea C, DENV-3 CH53489, and DENV-4 814669. Control antigen was a lysate of uninfected Vero cells. Phorbol Myristate Acetate at 20 lg/mL and ionomycin at 100 lg/mL were added as a positive control. A further negative control included cells incubated in media alone. All assays used a single lot of antigens, and each lot was tested for reactivity with monotypic DENV-immune donors [16] .
Cytokine Flow Cytometry
Laboratory assays and analysis of flow cytometry data was done under code, with the investigator blinded to the clinical information. With use of previously established methods [16] , PBMCs were stimulated with antigen at an antigen dilution of 1:20 for 18 h, at which time Brefeldin A was added; surface and intracellular cytokine staining was performed 6 h later. Cell phenotype was determined by the following surface stains: CD3 ) were gated and analyzed for cytokine production.
Data Analysis
All data were analyzed using Stata software. Comparison of median frequencies of DENV-specific cytokine-producing CD4 1 and CD8 1 T cells between symptomatic and subclinical infection groups was done using the Wilcoxon rank sum test. The number of patients with detectable (above negative control) DENV-specific T cell cytokine responses between the symptomatic and subclinical groups for each DENV serotype was compared using Fisher's exact test. Table 1 shows the characteristics of both groups defined on the basis of the clinical outcome during secondary infection: persons who experienced a febrile illness (ie, symptomatic group) and persons who had serologic evidence of infection without a recognized febrile illness (ie, subclinical group). Of the 10 patients in the symptomatic group, only 1 was hospitalized (this patient did not meet criteria for DHF), 6 had RT-PCR positive for DENV (5 with DENV-3 and 1 with DENV-1); the virus isolation results matched these findings.
RESULTS
Cohort Characteristics
DENV-Specific CD4 1 T Cell Cytokine Responses Figure 2 shows the frequency of DENV-specific cytokineproducing cells (TNFa, IFNc, and IL-2) in response to stimulation with each of the 4 DENV antigens in the PBMCs collected before the index secondary DENV infection. Regardless of clinical outcome, the majority of patients tested displayed a higher frequency of TNFa-producing cells after antigen stimulation, regardless of serotype, whereas the frequencies of IFNc and IL-2 producing cells were much smaller for both groups. The gating strategy is shown in Figure 1 . Overall (ie, across serotypes and cytokines), the frequencies of DENV-specific cytokine-producing CD4 1 T cells were higher in the subclinical group than in the symptomatic group. The percentage of IL-2-producing cells was higher in the subclinical group after in vitro stimulation with DENV-1, DENV-2, and DENV-4 antigens, although the finding was statistically significant for only DENV-4 (P 5 .01). The percentage of IFNc-producing cells responding to DENV-4 antigen was significantly higher in the subclinical group, as was the percentage of TNFa-producing cells responding to DENV-1 antigen. The number of patients who showed measurable CD4 1 T cell cytokine responses to DENV antigen stimulation is shown in Table 2 . For individual serotypes, there was a significantly higher proportion of subclinical IL-2 and IFNc responders after stimulation with DENV-4. An additional serotype-specific association among responders was also seen in TNFa (to DENV-2), although this finding did not reach statistical significance. As seen in Figure 3 , the subclinical group again showed overall higher median frequencies of cytokine-producing cells after stimulation with DENV antigens. As with the CD4 1 T cells, TNFa production was higher in the subclinical group after stimulation with DENV-1 antigen alone, whereas IFNc production was higher in the subclinical group after stimulation with DENV-4 antigen (P ,.05). No statistically significant differences in the pre-infection CD8 1 T cell characteristics between the symptomatic and subclinical groups were found with respect to IL-2 production. The number of patients who generated CD8 1 T cell cytokine responses after stimulation with DENV antigens is shown in Table 3 . There was a significantly higher proportion of subclinical TNFa responders after stimulation with DENV-1 antigen (P 5 .01), in addition to a higher proportion of subclinical IFNc responders to DENV-4, but this was not statistically significant (P 5 .06). No serotype-specific differences could be found with respect to IL-2.
Correlation Between Production of TNFa, IFNg, and IL-2 at the Single-Cell Level
Because of the hypothesized importance of polyfunctional T cells in determining the outcome of the memory T cell response to virus infection, we examined the production of each NOTE. The PRNT50 data refer to serum taken from all subjects as part of routine serologic surveillance in January 1998. The latter three columns refer to laboratory data taken at the time of acute illness. A PRNT50 value of 1 indicates an undetectable antibody response. An IgM/IgG ratio of ,1.8 indicates secondary infection, while a ratio .1.8 indicates primary infection. The PCR, Viral culture, and DENV IgM data were unavailable for the subclinical group as these are routine tests during symptomatic infection. a Hospitalized; did not meet WHO criteria for DHF.
of the 3 cytokines (TNFa, IFNc, and IL-2) at the single cell level among DENV-specific T cell populations. After DENV antigen stimulation, the majority of responders generated monofunctional rather than polyfunctional cells. Only 2 donors, both in the subclinical group, had significant numbers of polyfunctional cells (Figure 4 ). In addition, there was no statistically significant association between production of any 2 cytokines after antigen stimulation, regardless of serotype (data not shown). This was true in both the CD4 1 and CD8 1 T cell populations.
DISCUSSION
To our knowledge, this is the first article to describe the host immune response to DENV infection in relation to subclinical secondary infection and to do so using pre-illness samples collected as part of a prospective study. We report increased frequencies of DENV-specific, cytokine-producing CD4 1 and CD8 1 cells among schoolchildren who subsequently experienced subclinical, compared with symptomatic secondary DENV infections. Significantly higher frequencies with regard to IL-2 production were seen in the subclinical group after stimulation with DENV-4 antigen and higher frequencies after stimulation with DENV-1 and DENV-2, although these latter findings were not statistically significant. Differences between these subclinical and symptomatic groups in frequencies of DENV-specific IFNc-and TNFa-producing CD4 1 and CD8
1
T cells was also present, with a significantly higher frequency of TNFa-producing T cells seen in the subclinical group after stimulation with DENV-1 antigen and a higher frequency of IFNc-producing T cells after stimulation with DENV-4 antigen. We also noted a higher likelihood of being a responder in the subclinical group, particularly with respect to IFNc and IL-2 production, although the small sample size of the study precludes making definitive conclusions.
The pattern of T cell responses observed suggests a protective role for heterologous T cell responses through antiviral cytokine (ie, IFNc and IL-2) production. Other studies indicated that 1 intracellular cytokine production. TNFa, IFNc, and IL-2 production was measured in response to antigen stimulation with 4 dengue serotypes of presecondary infection PBMC from 27 Thai schoolchildren. Comparison groups are 10 children (triangles) who developed symptomatic infection and 17 children (circles) who had subclinical infection established retrospectively through dengue IgG ELISA and HI titers. Median percentage of cytokine-producing cells and P values to detect significant median differences using the Wilcoxon rank sum test are shown. pro-inflammatory cytokines, such as TNFa, generated in the heterologous response could have a harmful effect; in a previous study based on this same prospective cohort (albeit, involving a different group of children), our group compared in vitro cytokine secretion after antigen stimulation in PBMCs collected before secondary infection between children who were hospitalized and those who were not hospitalized during the subsequent secondary DENV infection. We reported that the only TNFa responses were among children who were hospitalized [17] . That study did not include a separate subclinical infection group. In addition, the previous study measured cytokine secretion over a 6-day period after antigen stimulation. The longer assay involves in vitro expansion of memory T cells and measures total cytokine secretion in the culture supernatants rather than the frequency of cytokine-producing cells and may reflect different aspects of the T cell functional response Figure 3 . CD8 1 intracellular cytokine production. TNFa, IFNc, and IL-2 production was measured in response to antigen stimulation with 4 dengue serotypes of presecondary infection PBMCs from 27 Thai schoolchildren. Comparison groups are 10 children (triangles) who developed symptomatic infection and 17 children (circles) who had subclinical infection established retrospectively through dengue IgG ELISA and HI titers. Median percentage of cytokine-producing cells and P values to detect significant median differences using the Wilcoxon rank sum test are shown. than the overnight ex vivo flow cytometry assay. However, there was a tendency for increased IFNc responses in the group with less severe symptoms, as seen in the present study. These differences in relative production of cytokines are consistent with other studies of DENV-specific memory T cells. We reported higher frequencies of TNFa-producing serotypecross-reactive DENV-specific memory CD4
1 T cells, compared with IFNc-producing cells in PBMCs from recipients of candidate monovalent, live DENV vaccines [18] . By contrast, we also found a less consistent hierarchy of responses among individual DENV epitope-specific CD8 1 T cells after primary infection [19] , and Imrie et al [20] showed altered cytokine responses at the clonal level among CD8 1 cells in Pacific Islanders after DENV-1 infection with a hierarchy of IFNc, TNFa, and IL-2. In these studies, however, no associations could be drawn with regard to symptoms after subsequent secondary infection. We cannot completely exclude the possibilities that the subclinical group had more recently experienced their previous DENV infection or had experienced 2 (or more) prior DENV infections, explaining both a higher frequency of DENV-specific antiviral cytokine-producing T cells and less symptomatic secondary infection. The narrow age range in the cohort and the absence of statistically significant differences between groups in the pre-illness PRNT data (Table 1 ) make this interpretation less likely, however, and our data still point to a relationship between the frequency of cytokine-producing T cells and subclinical infection. In addition to the immune response profile that we measured, a multiplicity of factors could influence the host immune response during secondary infection, resulting in the presence or absence of symptoms. For instance, we reported that certain HLA alleles were associated with disease severity in this population [21] . Although that study examined only symptomatic DENV-infected patients, it suggests that host genetic factors can be either protective or harmful in determining the presence or absence of symptoms in secondary infection. Other factors, including the immunologic similarities of DENV epitopes, the virus inoculum and/or the magnitude of the viremia during primary or secondary infection, the virulence of the strain [22] , and dysregulation of the complement system [23] , could contribute to differences in disease severity.
Statistically significant differences in cytokine-producing T cell frequencies after DENV-3 antigen stimulation were not prominent, although the majority of detectable infections in the symptomatic group involved DENV-3. Subgroup analysis of the patients with known DENV-3 infections did not provide further insights, largely because of small sample size. Although we cannot know with certainty the infecting serotype in the subclinical cases, our study and other data from Kamphaeng Phet province in that year indicate that DENV-3 was the predominant circulating serotype [24] . The response to other DENV serotypes detected in the flow cytometry assay, reflecting T cell responses generated by the earlier primary DENV infection, includes serotype-cross-reactive T cells that may be capable of blunting the severity of secondary infection with DENV-3.
Limitations of the current study include the use of an inactivated antigen preparation (Vero cell lysates) rather than overlapping peptides or known DENV epitopes. Although the drawbacks of this approach are that we could not identify specific immunodominant epitopes and that stimulation of CD8 1 T cells by the inactivated antigen is probably suboptimal, the use of DENV antigen allowed us to evaluate the immunologic response to the entire proteome of all 4 DENV serotypes using the small number of PBMCs available from these pediatric patients. Another limitation is that the symptomatic group represented only mild infection. A separate group of patients with DHF would permit further definition of immunologic associations with disease. In addition, we only studied the production of IFNc, TNFa, and IL-2. The production of other cytokines, such as IL-4 and IL-18, which have been implicated in dengue disease severity, might also be of interest [25, 26] .
In summary, we believe that our study supports the model that cytokine imbalance created by stimulation of cross-reactive T cells contributes to dengue disease severity and that ours is the first study to evaluate the predictive value of cytokine flow cytometry among children who later experienced secondary DENV infection. However, the relationship between crossreactive T cells and the role played by heterologous antibodies has yet to be examined. Another important line of inquiry would be to compare the findings of this study to those for genetically distinct human populations, such as in countries in the Western Hemisphere where dengue is endemic.
Establishing the relationships between antibody and T cell responses to dengue infection will be of particular value as vaccine development reaches fruition. The need to identify measurable correlates of protective immunity and to find immunologic markers predictive of such protection is critical. One recent study evaluated cell-mediated immunity during a phase 1 clinical trial of a chimeric tetravalent dengue vaccine [27] , although data from phase 2 and 3 trials has yet to be analyzed. Because of the unique challenges in developing a tetravalent vaccine for dengue, witnessed by the difficulties encountered by vaccine manufacturers until now [28] , a thorough understanding of the cellular immunology of secondary infection will be invaluable to evaluate the effectiveness of the several candidate vaccines currently in development. 
